Sir2501

Phase 2

Sir2501 is one of 3 therapeutic programs targeting Chemotherapy-induced Peripheral Neuropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chemotherapy-Induced Peripheral NeuropathyRecruiting

Chemotherapy-Induced Peripheral NeuropathyPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Chemotherapy-Induced Peripheral Neuropathy

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Phase 2

2 2

Nicotinamide Riboside

UUniversity of Oklahoma

Phase 2

1 3

Sir2501

SSironax USA, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Chemotherapy-Induced Peripheral Neuropathy

NCT07765446

Clinical

Trials by Indication[1]

Chemotherapy-induced Peripheral Neuropathy1 trial

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

Recruiting·SSironax USA, Inc.·Phase 2·NCT07765446·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sir2501. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sir2501. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sironax USA, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSironax USA, Inc.

Sir2501

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chemotherapy-induced Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News